微创医疗科学有限公司（00853.HK）近日发布业绩预告，为其上半年经营表现画出了清晰轮廓。公司预计，截至2026年6月30日的六个月里，其持续经营业务将实现同比12%至14%的营收增长。这一增速，无疑为市场注入了一剂强心针。
与此同时，公告还透露了利润端的关键信息。在报告期内，公司预计来自持续经营业务的净亏损将不超过5000万美元。这一数字，既反映了外部环境带来的挑战，也凸显了公司在成本控制与业务优化方面的努力。
整体来看，微创医疗正在经历一场深刻的转型与调整。营收的稳健增长，表明其核心业务依然具备强劲的韧性与扩张潜力；而亏损的收窄，则进一步印证了其战略聚焦的有效性。随着下半年行业旺季的到来，公司能否延续这一积极势头，成为市场关注的焦点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.